324 related articles for article (PubMed ID: 29606379)
1. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Yannuzzi NA; Smiddy WE
Ophthalmology; 2018 Sep; 125(9):1393-1400. PubMed ID: 29606379
[TBL] [Abstract][Full Text] [Related]
2. Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Smiddy WE
Ophthalmology; 2016 Sep; 123(9):1912-8. PubMed ID: 27425822
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility of Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Lin J; Gibbons A; Smiddy WE
Ophthalmol Retina; 2021 Jul; 5(7):656-663. PubMed ID: 33002672
[TBL] [Abstract][Full Text] [Related]
6. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
9. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
Messias K; Barroso RM; Jorge R; Messias A
Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
11. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
Maguire MG; Liu D; Glassman AR; Jampol LM; Johnson CA; Baker CW; Bressler NM; Gardner TW; Pieramici D; Stockdale CR; Sun JK;
JAMA Ophthalmol; 2020 Mar; 138(3):285-293. PubMed ID: 31999300
[TBL] [Abstract][Full Text] [Related]
12. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
[TBL] [Abstract][Full Text] [Related]
15. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
[TBL] [Abstract][Full Text] [Related]
16. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
17. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment.
Dong F; Yu C; Ding H; Shen L; Lou D
Medicine (Baltimore); 2016 Feb; 95(8):e2731. PubMed ID: 26937902
[TBL] [Abstract][Full Text] [Related]
19. Cost Analysis of Pneumatic Retinopexy versus Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment.
Elhusseiny AM; Yannuzzi NA; Smiddy WE
Ophthalmol Retina; 2019 Nov; 3(11):956-961. PubMed ID: 31416765
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
Figueira J; Silva R; Henriques J; Caldeira Rosa P; Laíns I; Melo P; Gonçalves Nunes S; Cunha-Vaz J
Ophthalmologica; 2016; 235(1):34-41. PubMed ID: 26630400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]